Patent 5,716,640 Scope and U.S. Claim Landscape for Biodegradable-Polymer Sustained-Release Microcapsules (W/O Emulsion)
US Patent 5,716,640 focuses on a post-encapsulation heat treatment window for biodegradable-polymer microcapsules made by W/O microencapsulation. The claims are narrow on the combination of (i) biodegradable polymer microcapsules formed on microencapsulation from an inner aqueous phase and an external oil phase and (ii) heating at or above the polymer glass transition temperature (Tg) but capped to avoid microcapsule aggregation, including specific constraints for peptide payloads and luteinizing hormone releasing hormone (LHRH) analogs. The strongest practical infringement exposure sits with process replicators that heat microcapsules near Tg with a “not too high” anti-aggregation goal, or within the specified 5–40°C above Tg range, and with injectable sustained-release products made from those microcapsules.
What does US 5,716,640 claim exactly, and what is the core claim “invention”?
Answer (claim architecture): The patent claims a process for producing sustained-release biodegradable-polymer microcapsules prepared from a W/O emulsion (aqueous interior, oil exterior) where the microcapsules are heated at ≥ Tg of the biodegradable polymer but not so high as to cause aggregation, with dependent claims narrowing the payload (peptides, LHRH) and polymer system (aliphatic polyesters) and tightening temperature and particle size ranges. Independent claim 1 also recites the injection-relevant end result in claim 11 and an injectable preparation in claim 13.
Independent claim 1 (method)
Claim 1 requires, in combination:
- A method of producing sustained-release microcapsules containing a biologically active substance.
- The microcapsules are made from an W/O emulsion:
- Inner aqueous phase contains the biologically active substance
- External oil phase contains a biodegradable polymer
- Microcapsules formed by microencapsulation of the biologically active substance with the biodegradable polymer.
- Heat treatment window:
- heated at a temperature not lower than the glass transition temperature (Tg) of the polymer
- but not so high as to cause aggregation of the microcapsules.
This “≥ Tg but not to aggregate” condition is the key functional limitation that distinguishes the process from mere drying/heating or from overheating that causes particle fusion.
Dependent claim 8 (temperature margin)
Claim 8 tightens the window:
- heating at about 5°C to 40°C higher than Tg.
This is an operational range that can be used for design-around if Tg is controlled or if heating is below the lower bound.
Independent claim 11 (product-by-process)
Claim 11 claims:
- Sustained-release microcapsules containing a biologically active substance,
- produced by the same process concept: heating microcapsules at ≥ Tg but not so high as to cause aggregation.
This product-by-process language can still be asserted against microcapsules whose structure/function matches and are alleged to be produced via the claimed process.
Independent claim 14 (method with explicit cap)
Claim 14 adds an explicit “upper ceiling”:
- heating at a temperature between:
- ≥ Tg (not lower than Tg),
- and Tg + 40°C.
This is the most literal, easy-to-map infringement window.
Which biologically active substances are covered (and how narrow is the peptide/LHRH coverage)?
Claim 2 (peptides by MW range)
Claim 2 limits “peptides” to:
- molecular weight about 200 to 80,000.
This covers a broad band of peptide therapeutics (including many hormones and hormone-releasing factors) but excludes small molecules and many very large biologics.
Claim 3 (LHRH and derivatives)
Claim 3 narrows peptide embodiments to:
- luteinizing hormone releasing hormone (LHRH) or derivatives.
This makes the claim set particularly relevant for:
- depot LHRH products,
- LHRH agonists/antagonists that can be framed as LHRH derivatives,
- peptide payloads where biodegradable polyester matrices and sustained-release microcapsules are used.
The claim does not name specific LHRH analogs (e.g., leuprolide, goserelin, triptorelin), but “derivatives” is a broad linkage term that could reach many commonly-used LHRH analogs if argued as derivatives within the patent’s interpretive scope.
What biodegradable polymers are covered, and what polymer limitations matter most for infringement?
Claim 4 (aliphatic polyester)
Claim 4 limits biodegradable polymer to:
Claim 5 (α-hydroxy acids homopolymer/copolymer)
Claim 5 limits further:
- polyester is a homopolymer or copolymer of α-hydroxy acids, or a mixture of homopolymer and/or copolymer.
This points to materials akin to polylactide/polyglycolide families conceptually, but the claim is specifically “α-hydroxy acids” framed.
Claims 6 and 7 (molecular weight and dispersity)
- Claim 6: weight average molecular weight about 3,000 to 30,000.
- Claim 7: dispersity about 1.2 to 4.0.
These parameters can become key infringement or non-infringement levers:
- a competitor using a biodegradable polyester outside those molecular weight/dispersity ranges has a credible argument against meeting the dependent claim limitations, assuming the claims are asserted as written (and not only under independent claim 1 depending on what counts are litigated).
What microcapsule product and particle size claims are included?
Claim 9 (mean particle diameter)
Claim 9 requires:
- mean particle diameter about 1 to 300 µm.
If a manufacturer’s process yields substantially smaller or larger particles, it may not meet claim 9 if that dependent claim is asserted. Claim 1 itself does not state a particle size limit, so particle size mostly matters for the dependent claim path.
Claim 10 (antiaggregation agent timing)
Claim 10 requires:
- heating is carried out after an antiaggregation agent is added to the microcapsules.
This gives a second axis of control:
- heating alone might satisfy claim 1 and claim 11/14 depending on interpretation, but claim 10 explicitly requires a sequence: antiaggregation agent then heating.
Claims 11–13 (product and injectable)
- Claim 11: sustained-release microcapsules produced by the heating process.
- Claim 12: antiaggregation agent added (in the product-by-process sense).
- Claim 13: an injectable preparation comprising those sustained-release microcapsules.
Injectable end-use claims increase regulatory and marketing exposure because the “product as made” is what ends up dosed.
How does the scope differ between “not so high as to aggregate” vs “Tg + 40°C”?
The patent contains two temperature formulations:
- Claim 1 / Claim 11: functional cap “not so high as to cause aggregation.”
- Claim 14: explicit upper bound: Tg + 40°C.
In litigation, explicit ranges are often easier to map to process controls. The “aggregation” formulation can introduce disputes about:
- what aggregation threshold counts,
- how aggregation is measured,
- whether a given degree of agglomeration is “aggregation” under claim construction,
- whether aggregation is evaluated immediately post-heating or after downstream handling.
Practical landscape implication:
- A competitor staying at Tg + 40°C or below could still be attacked under claim 1 if aggregation nonetheless occurs at that temperature in their specific system.
- A competitor staying below Tg could avoid both.
- A competitor slightly above Tg but with rigorous antiaggregation practices could argue the “not so high” functional cap is not met if aggregation is prevented.
Process elements that strongly constrain infringement risk
To infringe independent claim 1, the accused process must align with:
- formation via a W/O emulsion (inner aqueous phase + external oil phase with biodegradable polymer),
- microcapsules produced by microencapsulation of biologically active substance in that polymer,
- sustained-release microcapsules,
- and a heat treatment at ≥ Tg without causing aggregation.
Key constrained elements:
- If the accused process uses a different emulsion type (e.g., O/W) or different encapsulation strategy (coacervation without W/O), claim scope may not fit.
- If the payload is not within the claimed biologically active substance category as argued (peptide/LHRH is only in dependent claims), independent claim 1 still covers “biologically active substance” broadly, but the dependent claim scope narrows the most litigated hormone-depot space.
- If heating is not conducted at/above Tg, or heating is conducted above Tg without regard to aggregation (or clearly induces aggregation), claim 1 can be met, but the “not so high” cap could become a disputed factual fight.
What patents and patent estates most likely surround the microcapsule heat-treatment “window”?
US 5,716,640 is a process optimization patent aimed at microcapsule physical state control around polymer Tg to manage sustained release and particle stability. In this area, the surrounding patent landscape typically clusters around:
- biodegradable polyester microspheres/microcapsules made from W/O emulsions,
- peptide depot formulations using LHRH or peptide analog payloads,
- post-processing steps such as annealing/heating to tune polymer crystallinity or glassy state,
- antiaggregation approaches (anti-caking agents, surfactants, process additives),
- and injectability requirements.
However, without bibliographic confirmation (filing date, applicants/assignees, and the complete family and citation list), no reliable mapping to specific other US patents or expiration dates can be stated from the claim text alone.
Result: a complete U.S. “blocking/freeing” landscape cannot be produced from claim text alone while maintaining accuracy.
Is US 5,716,640 likely expired, and what does that mean for generic or biosimilar competition?
A precise exclusivity and expiration conclusion requires the patent’s grant and term structure data (filing date, payment of maintenance fees, PTA, and whether any term adjustments/extensions apply). Those details are not present in the prompt, so a definitive U.S. status cannot be provided here.
Result: no expiration timeline or Paragraph IV / biosimilar litigation exposure can be asserted without the patent’s actual legal status history.
Where infringement would concentrate commercially
Most exposed “scenario” for this claim set
Commercial exposure is highest for products that:
- use biodegradable aliphatic polyesters (α-hydroxy acid-based) in W/O microencapsulation for peptide depot,
- incorporate a post-encapsulation heating/annealing step at or above Tg,
- tune that step to avoid microcapsule aggregation,
- and are delivered as injectables containing those microcapsules.
Most exposed payload area
- LHRH derivatives in depot/injectable forms are the clearest dependent-claim landing zone (claims 2–3, 11–13).
Most exposed process variables
- polymer selection that matches “aliphatic polyester” and α-hydroxy acid polymerization,
- polymer molecular weight (3,000–30,000) and dispersity (1.2–4.0),
- heating temperature relative to measured Tg (5–40°C above Tg in claim 8; ≤ Tg + 40°C in claim 14),
- presence/timing of antiaggregation agent.
Claim-by-claim scope table (what must be present to read on each claim)
| Claim |
Category |
Required features (infringing combination) |
| 1 |
Method |
Sustained-release microcapsules from W/O emulsion: inner aqueous phase has biologically active substance; external oil phase has biodegradable polymer; microcapsules formed on microencapsulation; heat at ≥ Tg but not high enough to cause aggregation |
| 2 |
Dependent |
Biologically active substance is peptide MW ~200–80,000 |
| 3 |
Dependent |
Biologically active substance is LHRH or derivatives |
| 4 |
Dependent |
Biodegradable polymer is aliphatic polyester |
| 5 |
Dependent |
Aliphatic polyester is homopolymer/copolymer or mixture of α-hydroxy acids |
| 6 |
Dependent |
Weight average MW ~3,000–30,000 |
| 7 |
Dependent |
Dispersity ~1.2–4.0 |
| 8 |
Dependent |
Heating temp about 5°C to 40°C above Tg |
| 9 |
Dependent |
Mean particle diameter ~1–300 µm |
| 10 |
Dependent |
Antiaggregation agent added, then heating performed |
| 11 |
Product-by-process |
Sustained-release microcapsules produced by claim 1 heating regime |
| 12 |
Dependent |
Product of claim 11 with antiaggregation agent added |
| 13 |
Product |
Injectable preparation comprising the claim 11 microcapsules |
| 14 |
Method |
Heating temp between Tg (not lower than Tg) and Tg + 40°C |
Key design-around levers (process and formulation)
- Stay below Tg: Heating below Tg avoids independent claim 1’s “not lower than Tg” condition.
- Control for aggregation differently: If accused process uses Tg heating but demonstrates no aggregation per claim interpretation and tests, claim 1 becomes harder to satisfy under the “not so high” functional cap.
- Avoid the W/O architecture: If encapsulation uses a different emulsion system or process route, the W/O + inner aqueous + external oil phase combination fails.
- Polymer selection outside dependent limits: Use a polymer that is not an “aliphatic polyester” or is not within α-hydroxy acid-based definitions, or outside MW/dispersity bands if dependent claims are asserted.
- Avoid injectable product formulation: A manufacturer making microcapsules but not dosing them as injectables may reduce practical enforcement focus on claim 13, though claim 1/11 remain relevant.
Key Takeaways
- US 5,716,640 is centered on a Tg-based heat treatment window for biodegradable-polymer microcapsules made by W/O microencapsulation, with the core limitation being heated at ≥ Tg but not so high as to cause aggregation.
- Dependent claims narrow the most commercially relevant space to peptides (MW ~200–80,000) and LHRH or derivatives, and to aliphatic polyester systems from α-hydroxy acids with specific MW/dispersity.
- Temperature margins matter: claim 8 provides Tg + 5°C to Tg + 40°C, while claim 14 provides Tg to Tg + 40°C.
- The strongest enforcement hooks for injectable depot competitors are claims 11 (product-by-process) and 13 (injectable preparations) tied to the Tg-based heating process.
FAQs
1) Does US 5,716,640 require that the microcapsules be crystalline or amorphous?
No. The claims are tied to heating relative to glass transition temperature and avoidance of aggregation, not directly to crystallinity state.
2) Can the patent cover peptides outside 200–80,000 Da?
Dependent claim 2 would not, but independent claim 1 is not limited to that range.
3) Is antiaggregation agent required for infringement of claim 1?
No. Antiaggregation agent is only expressly required in dependent claim 10 (and claim 12 tied to the product).
4) If heating is performed at Tg + 45°C, can a claim still be met?
Claim 14 would likely not. Claim 1 could still be asserted depending on whether the process is argued to avoid “aggregation” despite the higher temperature, but the functional cap creates factual dependency.
5) What is the primary claim risk for an injectable LHRH depot process?
Processes using W/O microencapsulation of LHRH derivatives in biodegradable aliphatic polyesters and performing a Tg-based annealing step in the non-aggregation window, producing sustained-release injectable microcapsules.
References
No external sources were cited because the prompt provides only the claim text; no bibliographic or legal-status sources were included.
